

Press Release

RESISTANCE MECHANISMS OF *DEINOCOCCUS* PRESENTED AT A "GORDON RESEARCH CONFERENCE"

- The work of one of the DEINOVE doctoral students, resulting from collaboration between DEINOVE and "UMR-MD1 TMCD2" laboratory (Aix-Marseille University) held the attention of the scientific committee of this prestigious conference. It was presented on April 30 as part of the "Multi-Drug Efflux Systems" session to an audience of scientists from around the world
- This is recognition of the scientific quality of DEINOVE's work, but also the relevance of the State's support, which partially funds the Company's research through two CIFRE contracts¹, including that of doctoral student Erika Boulant via the ANRT²

Montpellier, May 5, 2015 - DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using *Deinococcus* bacteria as host strains, today announced that one of its researchers, Erika Boulant, was selected by the scientific committee of the prestigious "Gordon Research Conference" to present her work as part of the "Multi-Drug Efflux Systems" session held in Barga, Italy, from April 26 to May 1, 2015 (<https://www.grc.org/programs.aspx?id=13928>).

The Gordon Research Conferences constitute an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies. These scientific conferences were initiated by Johns-Hopkins University in the USA.

Erika Boulant's work focuses on the study of the mechanisms of resistance to fermentation products in *Deinococcus*. This is applied research to improve the performance of the strains. Erika joined the DEINOVE team as part of the CIFRE programme¹ and works in the "UMR-MD1 Transporteurs Membranaires, Chimiorésistance et Drug-Design" laboratory in Marseille. She is one of the two researchers in the team who benefit from this type of state funding through the ANRT².

"It is a pleasure and an honour to see the work of our young researchers recognised by a high-level organisation such as the Gordon Research Conferences. Erika's work is directly applicable to the improvement of a Deinococcus-based industrial production process", commented Jean-Paul Leonetti, VP of R&D at DEINOVE. *"This is recognition of the quality of State-funded CIFRE contracts, which support this collaborative research project",* added Jean-Michel Bolla, Team leader in Marseille.

¹ The CIFRE programme - Industrial Agreements for Training through Research (Conventions Industrielles de Formation par la REcherche) - subsidises any company under French law that hires a doctoral student for research collaboration with a public laboratory. The work leads to a thesis defence in three years. Here, Erika Boulant, one of two researchers benefiting from this programme in DEINOVE laboratories, works with Aix-Marseille University.

² French National Association for Research and Technology (Association Nationale de la Recherche et de la Technologie)

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs over 40 people in its new offices and laboratories located in Montpellier, France.

More information at www.deinove.com

CONTACTS

DEINOVE

Emmanuel Petiot

CEO

Tel.: +33 (0) 4 48 19 01 28

emmanuel.petiot@deinove.com

Jean-Paul Leonetti

VP R&D

Tel.: +33 (0) 4 48 19 01 00

jean-paul.leonetti@deinove.com

ALIZE RP, Press Relations

Caroline Carmagnol / Valentine Boivin

Mobile: +33 (0) 6 83 48 23 27

deinove@alizerp.com

Coralie Martin

Communication, Marketing and IR Manager

Tel.: +33 (0) 4 48 19 01 60

coralie.martin@deinove.com

ALDEI
LISTED
NYSE
ALTERNEXT